Vaxinano’s technology in use against the coronavirus pandemic.
Tuesday, June 30th 2020
The French research national agency (ANR) has granted Vaxinano funding to develop an innovative vaccine against Covid-19.
In the current context of the Covid-19 pandemic, the sanitary restrictions currently in place are only temporary.
It appears that only a vaccine will limit the dramatic consequence of the virus, as people cannot remain housebound and economic activity must restart.
Vaxinano has received funds from the French national research agency (ANR) to develop a nasal vaccine, without adjuvant, against Covid-19.
Coordinated by Pr Dimier-Poisson from the University of Tours (France), the Nano-SARS_CoV2 consortium, involving academics, pre-industrial structures and the biotech sector, uses an innovative approach to produce the vaccine using Vaxinano’s technology.
“Our technology totally fits with the current global need: stable, inexpensive, versatile, easy-to-use… and efficient for triggering a protective immunity !
We hope that this first stone will pave the route of the anti-SARS_CoV2 vaccine.” said Didier Betbeder, CEO of Vaxinano.